BRPI0808293A2 - "composições para administração nasal" - Google Patents

"composições para administração nasal"

Info

Publication number
BRPI0808293A2
BRPI0808293A2 BRPI0808293A BRPI0808293A BRPI0808293A2 BR PI0808293 A2 BRPI0808293 A2 BR PI0808293A2 BR PI0808293 A BRPI0808293 A BR PI0808293A BR PI0808293 A BRPI0808293 A BR PI0808293A BR PI0808293 A2 BRPI0808293 A2 BR PI0808293A2
Authority
BR
Brazil
Prior art keywords
compositions
nasal administration
nasal
administration
Prior art date
Application number
BRPI0808293A
Other languages
English (en)
Inventor
Godin Biana
Touitou Elka
Duchi Shaher
Original Assignee
Yissum Research Development Company Of The Hebrew Univ Of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew Univ Of Jerusalem filed Critical Yissum Research Development Company Of The Hebrew Univ Of Jerusalem
Publication of BRPI0808293A2 publication Critical patent/BRPI0808293A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI0808293A 2007-03-29 2008-03-30 "composições para administração nasal" BRPI0808293A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90734007P 2007-03-29 2007-03-29
PCT/IL2008/000445 WO2008120207A2 (en) 2007-03-29 2008-03-30 Compositions for nasal delivery

Publications (1)

Publication Number Publication Date
BRPI0808293A2 true BRPI0808293A2 (pt) 2019-09-24

Family

ID=39731229

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808293A BRPI0808293A2 (pt) 2007-03-29 2008-03-30 "composições para administração nasal"

Country Status (10)

Country Link
US (1) US8911751B2 (pt)
EP (1) EP2139449A2 (pt)
JP (1) JP2010522741A (pt)
CN (2) CN101720220A (pt)
AU (1) AU2008234535A1 (pt)
BR (1) BRPI0808293A2 (pt)
CA (1) CA2683217A1 (pt)
EA (1) EA200901319A1 (pt)
MX (1) MX2009010289A (pt)
WO (1) WO2008120207A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2009121039A2 (en) 2008-03-28 2009-10-01 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2010080909A1 (en) 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20120171246A1 (en) 2009-09-10 2012-07-05 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
DK2706982T4 (da) 2011-05-13 2021-05-10 Euro Celtique Sa Intranasale farmaceutiske dosisformer omfattende naloxon
EP3415139B8 (en) * 2011-06-14 2022-05-18 Neurelis, Inc. Administration of benzodiazepine
US9757468B2 (en) 2013-03-13 2017-09-12 The Regents Of The University Of California Intranasal administration of guanidinylated aminoglycosides
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
WO2015077714A1 (en) 2013-11-22 2015-05-28 Yale University Chimeric vsv virus compositions and methods of use thereof for treatment of cancer
WO2015140790A1 (en) * 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
US10052339B2 (en) * 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
DK3200828T3 (da) * 2014-10-03 2020-10-12 Lachesis Biosciences Ltd Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser
US20170326102A1 (en) * 2014-11-27 2017-11-16 Cipla Limited Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
WO2016097425A1 (de) * 2014-12-19 2016-06-23 Thc Pharm Gmbh Cbd-haltiges getränk
WO2016161537A1 (en) * 2015-04-08 2016-10-13 Maxinase Life Sciences Limited Bioadhesive compositions for intranasal administration of granistron
WO2016168197A1 (en) 2015-04-15 2016-10-20 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
GB201508656D0 (en) 2015-05-20 2015-07-01 Sunstone Ip Systems Ltd Portable power generating apparatus
GB2544468A (en) * 2015-11-12 2017-05-24 Jaytee Biosciences Ltd Liquid formulation
US10675252B2 (en) 2015-12-05 2020-06-09 Canna-B Cure Ltd Veterinary composition and methods for production and use
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
JP2019537628A (ja) * 2016-11-02 2019-12-26 ティクン オラム リミテッドＴｉｋｕｎ Ｏｌａｍ ＬＴＤ 併用療法
US20190314297A1 (en) 2016-11-02 2019-10-17 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
KR101810160B1 (ko) 2017-06-30 2018-01-25 주식회사 셀리제코스메틱 생리활성물질이 봉입된 에토좀 제조 방법, 에토좀 조성물 및 에토좀 조성물을 포함하는 화장료 조성물
WO2019049145A1 (en) 2017-09-11 2019-03-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. COMPOSITIONS AND METHODS FOR NASAL BRAIN MEDICATION ADMINISTRATION FOR SYSTEMIC EFFECT
EP3717014A1 (en) 2017-11-29 2020-10-07 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cannabinoids compositions and methods
WO2020018705A1 (en) 2018-07-17 2020-01-23 Yale University Methods for treatment of cancer using chikungunya-vsv chimeric virus
JP7326445B2 (ja) 2018-12-11 2023-08-15 ディスラプション・ラブズ・インコーポレイテッド 治療剤の送達のための組成物並びにその使用及び製造方法
US11523986B2 (en) * 2019-03-22 2022-12-13 Dbbh, Llc Intranasally administered antihistamines and uses thereof
US20220313682A1 (en) * 2019-08-07 2022-10-06 Aclipse One Inc. Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
WO2021091905A1 (en) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Liposomal formulations for delivery of cannabinoids and methods of making thereof
WO2021242913A1 (en) * 2020-05-26 2021-12-02 Strategic Drug Solutions, Inc. Formulations and methods for treating erectile dysfunction
WO2021247447A1 (en) * 2020-06-01 2021-12-09 Luke Klele Antiviral compositions
WO2022011460A1 (en) * 2020-07-13 2022-01-20 Hexo Operations Inc. Transmucosal cannabis compositions with enhanced permeation properties
EP4274618A1 (en) * 2021-01-08 2023-11-15 Neurelis, Inc. Methods and compositions for rapid delivery of anti-seizure therapeutics
WO2023004427A1 (en) * 2021-07-23 2023-01-26 University of Sassari Treatment of severe and uncomplicated malaria
IT202200009092A1 (it) * 2022-05-04 2023-11-04 Emilia ARMENIA Transetosomi per la veicolazione di farmaci
WO2024042466A1 (en) 2022-08-22 2024-02-29 University Of Tartu Brain penetrating peptides and methods of use thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3650772T2 (de) 1985-04-27 2003-04-03 Hoffmann La Roche Derivate von Indazole-3-carboxamide und -3-carboxylsäure
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6350458B1 (en) * 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
ATE399565T1 (de) 1998-07-07 2008-07-15 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht- irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
US20020048551A1 (en) * 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
CA2379365C (en) 1999-07-26 2009-11-17 Sk Corporation Transnasal anticonvulsive compositions and modulated process
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1411897A4 (en) 2001-06-26 2010-08-11 Yissum Res Dev Co COMPOSITIONS AND METHODS FOR INTRA-CELLULAR DELIVERY
CA2469224A1 (en) 2001-12-06 2003-06-12 Ufc Limited Trioxane derivatives
ES2197001B1 (es) 2002-03-26 2004-11-16 Laboratorios Vita, S.A. Procedimiento de obtencion de un compuesto farmaceuticamente activo.
AU2003227517A1 (en) 2002-05-23 2003-12-12 Danmarks Farmaceutiske Universitet Pharmacologically active salts
JP2007510736A (ja) * 2003-11-05 2007-04-26 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 多発性硬化症に付随する症状を治療するためのデルタ−９−ｔｈｃ組成物及び方法
WO2005107467A2 (en) 2004-05-03 2005-11-17 Descartes Therapeutics, Inc. Compositions including opioids and methods of their use in treating pain
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
NZ578727A (en) 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
US7855196B2 (en) * 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP1933809B1 (en) * 2005-10-11 2012-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
DE102006027793A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
EP1964552B1 (en) 2007-03-02 2009-08-26 Flamek Corp OÜ Analgesic composition of topically applied nonsteoridal antiinflammatory drugs and opioids

Also Published As

Publication number Publication date
CA2683217A1 (en) 2008-10-09
CN102743740A (zh) 2012-10-24
JP2010522741A (ja) 2010-07-08
EP2139449A2 (en) 2010-01-06
EA200901319A1 (ru) 2010-08-30
AU2008234535A1 (en) 2008-10-09
WO2008120207A2 (en) 2008-10-09
US20090047234A1 (en) 2009-02-19
US8911751B2 (en) 2014-12-16
WO2008120207A3 (en) 2009-01-29
CN101720220A (zh) 2010-06-02
MX2009010289A (es) 2010-03-08

Similar Documents

Publication Publication Date Title
BRPI0808293A2 (pt) "composições para administração nasal"
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTC2140867I2 (lt) Farmacinė kompozicija
BRPI0810928A2 (pt) "composição farmacêutica"
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0815452A2 (pt) "equipamento para gastropexia"
BRPI0810646A2 (pt) " compostos farmacêuticos ".
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0913806A2 (pt) "composição"
GB0706744D0 (en) Nasal administration
BRPI0719393A2 (pt) Composição farmacêutica
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
DK2018158T3 (da) Ny racecadotril administrationsform
BRPI0820198A2 (pt) composições farmacêuticas
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0819566A2 (pt) "composições antissépticas para tecidos"
HK1217090A1 (zh) 用於局部鼻施用的奧洛他定製劑
BRPI0812000A2 (pt) Métodos e composições para administração de oxibutinina
DK2271321T3 (da) Farmaceutisk sammensætning 271

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B25D Requested change of name of applicant approved

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL)

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.